Tysabri Patients Diagnosed With Severe Liver Damage or Melanoma
Tuesday, March 25, 2008
Mark & Associates, P.C. & MacDonald Rothweiler Eisenberg L.L.P. announced that they are evaluating claims of patients treated with the drug Tysabri(r) who have been diagnosed with severe liver damage or melanoma. The announcement comes shortly after the manufacturers of Tysabri, Biogen Idec Inc. (Nasdaq:BIIB) and Elan Corp. plc (NYSE:ELN), warned about reports of liver toxicity in patients treated with the drug following its approval by the Food and Drug Administration, and a letter in the New England Journal of Medicine cautioned doctors about two aggressive cases of malignant melanoma that occurred shortly after the drug was administered. Tysabri(r) patients…Continue » Posted in Dangerous Drugs • Tysabri